Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US00439U1043
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG001NMDXS6
GRCE
Grace Therapeutics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Grace Therapeutics, Inc.
ISIN
US00439U1043
TICKER
GRCE
MIC
XNAS
REUTERS
GRCE.OQ
BLOOMBERG
GRCE US
Mi., 05.08.2026       Grace Therapeutics
US00439U1043

Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 28.07.2026       Grace Therapeutics
US00439U1043

FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Grace Therapeutics
US00439U1043

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 27.05.2026       Grace Therapeutics
US00439U1043

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (“Grace” or “the Company”) (NASDAQ: GRCE) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to d...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Grace Therapeutics
US00439U1043

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or the "Company") (NASDAQ: GRCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 15.05.2026       Grace Therapeutics
US00439U1043

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or the "Company") (NASDAQ: GRCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Grace Therapeutics
US00439U1043

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information ...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Grace Therapeutics
US00439U1043

PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarach...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       Grace Therapeutics
US00439U1043

PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemo...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 12.02.2026       Grace Therapeutics
US00439U1043

FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 13.11.2025       Grace Therapeutics
US00439U1043

Announced U.S. Food and Drug Administration (FDA) Acceptance for Reviewof New Drug Application (NDA) for GTx-104...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 11.11.2025       Grace Therapeutics
US00439U1043

STRIVE-ON Results Accepted for Late-Breaking Presentation STRIVE-ON Results Accepted for Late-Breaking Presentation...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 18.09.2025       Grace Therapeutics
US00439U1043

Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 04.09.2025       Grace Therapeutics
US00439U1043

PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announc...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 12.08.2025       Grace Therapeutics
US00439U1043

Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 23.06.2025       Grace Therapeutics
US00439U1043

Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 13.06.2025       Grace Therapeutics
US00439U1043

PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemor...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 13.02.2025       Grace Therapeutics
US00439U1043

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 10.02.2025       Grace Therapeutics
US00439U1043

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 10.02.2025       Grace Therapeutics
US00439U1043

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 07.01.2025       Grace Therapeutics
US00439U1043

PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal suba...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 13.11.2024       Grace Therapeutics
US00439U1043

STRIVE-ON Data Readout Expected First Calendar Quarter 2025; NDA Submission on Track for 1H Calendar 2025...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.10.2024       Grace Therapeutics
US00439U1043

Instrument ID [21219368] (L8S - US00439U1043) suspended...
Zur Nachricht
Grace Therapeutics
Charts & Research Termsheets Terminal
Permalink